Many Australian medicine sponsors are familiar with the concept of a Qualified Person for Pharmacovigilance (QPPV), particularly if they operate internationally. However, there is often confusion around what the role means in the Australian context and how it differs from pharmacovigilance arrangements in other jurisdictions.

Australian sponsors are expected to have a QPPV as part of their pharmacovigilance system. In addition, sponsors must have a pharmacovigilance contact person residing in Australia who can be contacted by the Therapeutic Goods Administration (TGA).

While these requirements may appear straightforward, the real challenge lies in ensuring that the individuals fulfilling these roles have appropriate oversight of the Australian pharmacovigilance system and understand the unique characteristics of the Australian market.

Pharmaceutical companies often rely on various external vendors to support activities such as adverse event reporting, safety data processing, and regulatory intelligence. This responsibility extends beyond traditional vendors to include entities such as social media influencers and market research organisations (MROs) that may receive and process safety information. Ensuring that these vendors meet rigorous standards for quality, compliance, and data integrity is essential for maintaining the safety and efficacy of medicinal products.